Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

Investing in rapidly expanding biotech stocks can be a worthwhile long-term investment. Just one successful drug or device ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

As weight-loss drugs have exploded in popularity this past year, part of the craze has been members of the public wondering which celebrities are on Ozempic.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) e estimate Rivian’s stock price to be $140.00 per share. Our estimated stock ...

StudyFinds' Dr. Faith Colemans explains why shopping for weight loss drugs online may save you money but endanger your health ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

During FDA-declared shortages, pharmacists can legally make compounded versions of brand-name medications. But drugmakers and ...

Eli Lilly has surpassed that S&P 500 five years in a row when Wall Street recognized its enormous opportunity in obesity ...

The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.